Ultragenyx (RARE) Q3 Earnings Performance Compared to Estimates

Ultragenyx (RARE) reported impressive financial results for the quarter ending September 2024. The company achieved revenue of $139.49 million, marking a significant year-over-year increase of 42.3%. Additionally, the earnings per share (EPS) was reported at - $1.40, an improvement from - $2.23 from the year prior.

This reported revenue exceeded Wall Street expectations, as it was 4.04% higher than the Zacks Consensus Estimate of $134.08 million. The EPS also surpassed estimates, with a consensus of - $1.45, leading to an EPS surprise of 3.45%.

Investors typically pay close attention to headline numbers like revenue and earnings. However, analyzing key metrics gives a deeper understanding of a company's true performance. These vital metrics contribute significantly to overall financial results, providing investors insight into future stock performance.

Key Metrics Performance

In the recently reported quarter, Ultragenyx's performance in terms of widely monitored metrics was as follows:

• Product Sales - Dojolvi: Generated $21.37 million, beating the average estimate of $20.57 million. This marks a 29.1% increase from the previous year.
• Product Sales - Evkeeza: Recorded $10.66 million, which was significantly higher than the average estimate of $7.09 million.
• Product Sales - Mepsevii: Achieved $9.62 million, surpassing the average estimate of $7.34 million.
• Total Product Sales: Totaled $77.25 million, surpassing the six-analyst average estimate of $63.28 million, showing an impressive 82.4% year-over-year growth.
• Product Sales - Crysvita: Reached $35.60 million, exceeding the six-analyst average estimate of $28.92 million.
• Non-Cash Collaboration Royalty Revenue: Reported at $62.24 million, which was lower than the estimated $68.96 million from five analysts, although this still reflects a remarkable 203% increase compared to the same quarter last year.

Overall, Ultragenyx's performance in the third quarter highlighted strong growth in product sales and improved earnings, providing a more favorable outlook as the company moves forward.

Stock Performance Overview

In terms of market response, shares of Ultragenyx have experienced a -2.6% decline over the last month, contrasting with a -0.5% change in the Zacks S&P 500 composite. Currently, Ultragenyx holds a Zacks Rank of #3 (Hold), suggesting that its performance may align with that of the broader market in the near term.

Earnings, Metrics, Performance